<DOC>
	<DOCNO>NCT01476124</DOCNO>
	<brief_summary>This double-blind study evaluate pharmacokinetics single dose morphine gabapentin derive gabapentin enacarbil ( GEn ) administration morphine GEn alone combination well tolerability morphine administer GEn . The dose GEn 600 mg administer food . Morphine/morphine placebo administer 2 hour prior GEn/GEn placebo fast state . A 60 mg dose control release formulation morphine give . Blood sample evaluation gabapentin , morphine morphine-6-glucuronide collect . The pharmacodynamic effect co-administering treatment assess use visual analog scale somnolence/sedation , dizziness nausea .</brief_summary>
	<brief_title>Drug Drug Interaction Study With Gabapentin Enacarbil Morphine</brief_title>
	<detailed_description>This double-blind study evaluate pharmacokinetics single dose morphine gabapentin derive gabapentin enacarbil ( GEn ) administration morphine GEn alone combination well tolerability morphine administer GEn . The dose GEn 600 mg administer food . Morphine/morphine placebo administer 2 hour prior GEn/GEn placebo fast state . A 60 mg dose control release formulation morphine give . Blood sample evaluation gabapentin , morphine morphine-6-glucuronide collect . The pharmacodynamic effect co-administering treatment assess use visual analog scale somnolence/sedation , dizziness nausea .</detailed_description>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Subject healthy determine responsible physician , base medical evaluation include medical history , physical examination , clinical laboratory test , 12 lead ECG . A subject clinical abnormality laboratory parameter outside reference range population study may include investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure Subject male 18 65 year age inclusive , time signing informed consent Subject body weight &gt; 55 kg body mass index ( BMI ) within range 19 30 kg/m2 ( inclusive ) Subject capable give write informed consent , include compliance requirement restriction list informed consent form Subject QTcB &lt; 450 m Subject creatinine clearance ( CrCl ) &gt; 80 mL/min . The CrCl estimate use Cockcroft Gault equation . Details CrCl calculation provide Study Procedures Manual ( SPM ) Subject aspartate aminotransferase ( AST ) , ALT , alkaline phosphatase within reference range screen visit . Isolated bilirubin &gt; 1.5 Ã— ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % total bilirubin Subject positive prestudy drug alcohol screen result . At minimum , drug screen include alcohol , cotinine , amphetamine , barbiturate , cocaine , opiates , cannabinoids , benzodiazepine Subject positive prestudy ( within 3 month Screening ) hepatitis B surface antigen positive hepatitis C antibody result Subject positive prestudy human immunodeficiency virus ( HIV ) antibody result Subject history regular alcohol consumption within 6 month study define : average intake &gt; 14 drinks/week . One drink equivalent ( 12 g alcohol ) = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) 80 proof distil spirit . Subject participate clinical trial receive investigational product within following time period first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) Subject expose 4 new chemical entity within 12 month first dose day Subject use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) first dose study treatment , unless opinion investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Subject history sensitivity gabapentin , morphine , component thereof , history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation study Subject 's participation study would result donation blood blood product excess 500 mL within 56day period Subject unwilling unable follow procedure outline protocol Subject screen heart rate &lt; 45 &gt; 100 bpm , systolic blood pressure &gt; 140 &lt; 100 mm Hg , diastolic blood pressure &gt; 90 &lt; 60 mm Hg semi supine position value ( ) return within reference range upon retest . Subject postural hypotension demonstrate screen medical ( defined fall systolic pressure 30mmHg and/or fall diastolic pressure 20mmHg stand 3 minute ) history clinically significant symptomatic postural hypotension vaso vagal episode Subject smoke 5 cigarette equivalent/day . Subjects continue smoking/nonsmoking habit throughout study apart refrain smoke study day Subject history presence clinically significant cardiovascular , pulmonary , hepatic , renal , hematologic , GI , endocrine , immunologic , dermatologic , neurologic psychiatric disease Subject history seizure febrile seizure child Subject received medication know chronically alter drug absorption elimination process within 30 day first dose administration , opinion Sponsor investigator Subject creatine kinase value great ULN explainable recent strenuous exercise value return within reference range upon retest . Subject current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) Subject mentally legally incapacitated Subject history respiratory depression , acute severe bronchial asthma , hypercarbia Subject suspect paralytic ileus chronic constipation Has active suicidal plan/intent active suicidal thought past 6 month . Has history suicide attempt last 2 year 1 lifetime suicide attempt</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>